This site is intended for Healthcare professionals only.

Alembic Pharma associate co gets USFDA fast track designation for cancer drug


Alembic Pharma associate co gets USFDA fast track designation for cancer drug

New Delhi: Drug firm Alembic Pharmaceuticals said the US health regulator has granted fast track designation to its associate company Rhizen Pharmaceuticals SA’s RP6530 (tenalisib), used in the treatment of cancer.

“The US Food and Drug Administration (USFDA) has granted Fast Track Designation for RP6530 (tenalisib)…for the treatment of patients with relapsed/refractory peripheral T- cell lymphoma (PTCL),” Alembic Pharmaceuticals said in a BSE filing.

Fast track designation is awarded to drugs that treat a serious condition and fill an unmet medical need, it added.



Source: PTI
0 comment(s) on Alembic Pharma associate co gets USFDA fast track designation for cancer drug

Share your Opinion Disclaimer

Sort by: Newest | Oldest | Most Voted